Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening
Purpose This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia...
Gespeichert in:
Veröffentlicht in: | Archives of gynecology and obstetrics 2022, Vol.305 (1), p.87-93 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 93 |
---|---|
container_issue | 1 |
container_start_page | 87 |
container_title | Archives of gynecology and obstetrics |
container_volume | 305 |
creator | Peace, Stephanie M. Jennings, Ashley J. |
description | Purpose
This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia (CIN) 3 or cancer within this population.
Methods
We conducted a retrospective chart review of women age 30–65 with intact cervices who had discordant cotesting results between January 1, 2013 and September 1, 2018, at an academic medical center. We used the
t
test for continuous variables and the Chi-square test for categorical variables to compare women with and without CIN3 + . To identify factors associated with CIN3 + , we performed univariate and multivariate logistic regression.
Results
The primary outcome was the prevalence of CIN3 + based on pathologic diagnosis following biopsy or excisional procedure. Among 375 patients with discordant co-testing, the mean age was 43.8 years, 58.4% were parous, and 84.8% were white. Overall, 43/375 (12.0%) had CIN3 + and 7/375 (1.9%) had AIS. On logistic regression, only parity ≥ 1 (
p
= 0.04, adjusted OR = 2.23, CI = 1.06–4.68) was significantly associated with CIN3 + . HPV-18 was less likely to be associated with CIN3 + (
p
= 0.02, adjusted OR 0.08, CI 0.01–0.65) but was present in 43% of AIS cases. HPV16 and other HR-HPV strains were highly associated with CIN3 + .
Conclusion
Women with discordant cotesting are at significant risk for CIN3 + . We recommend that biopsy be performed at the time of indicated colposcopy for all patients with discordant cotesting to assess for high-grade dysplasia. |
doi_str_mv | 10.1007/s00404-021-06208-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2576655790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2621822034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-178e994250ece470462bafc2a223d59eebf0124fce05cd5ebcd9df5eaabb18163</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq0KVBbaF-gBWeLSQw3jie0kxwrRUgmJPdBeLceZBKNssti7K-3b42WXVuqBk8eab_4ZfYx9kXApAcqrBKBACUApwCBUAj-wmVQFCiilPGIzqHc1mPKEnab0BCCxqsxHdlIobWQpzYzZeaSNG2j0xKeOP4b-UfTRtcTbbVoOLgXHw8j9djUNU78VI_VuFTb0jd_O_4jllMLuxz3FTfBu4N7lpMiTj0RjGPtP7LhzQ6LPh_eM_f5x83B9K-7uf_66_n4nvJL1SsiyorpWqIE8qRKUwcZ1Hh1i0eqaqOny8arzBNq3mhrf1m2nybmmkZU0xRn7us9dxul5TWllFyF5GgY30rROFnVpjNZlDRm9-A99mtZxzNdZNCgrRChUpnBP-TilFKmzyxgWLm6tBLvTb_f6bdZvX_VbzEPnh-h1s6D278ib7wwUeyDl1thT_Lf7ndgXppCQpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621822034</pqid></control><display><type>article</type><title>Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Peace, Stephanie M. ; Jennings, Ashley J.</creator><creatorcontrib>Peace, Stephanie M. ; Jennings, Ashley J.</creatorcontrib><description>Purpose
This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia (CIN) 3 or cancer within this population.
Methods
We conducted a retrospective chart review of women age 30–65 with intact cervices who had discordant cotesting results between January 1, 2013 and September 1, 2018, at an academic medical center. We used the
t
test for continuous variables and the Chi-square test for categorical variables to compare women with and without CIN3 + . To identify factors associated with CIN3 + , we performed univariate and multivariate logistic regression.
Results
The primary outcome was the prevalence of CIN3 + based on pathologic diagnosis following biopsy or excisional procedure. Among 375 patients with discordant co-testing, the mean age was 43.8 years, 58.4% were parous, and 84.8% were white. Overall, 43/375 (12.0%) had CIN3 + and 7/375 (1.9%) had AIS. On logistic regression, only parity ≥ 1 (
p
= 0.04, adjusted OR = 2.23, CI = 1.06–4.68) was significantly associated with CIN3 + . HPV-18 was less likely to be associated with CIN3 + (
p
= 0.02, adjusted OR 0.08, CI 0.01–0.65) but was present in 43% of AIS cases. HPV16 and other HR-HPV strains were highly associated with CIN3 + .
Conclusion
Women with discordant cotesting are at significant risk for CIN3 + . We recommend that biopsy be performed at the time of indicated colposcopy for all patients with discordant cotesting to assess for high-grade dysplasia.</description><identifier>ISSN: 0932-0067</identifier><identifier>ISSN: 1432-0711</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-021-06208-2</identifier><identifier>PMID: 34561716</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Biopsy ; Cellular biology ; Cervical cancer ; Colposcopy ; Early Detection of Cancer ; Endocrinology ; Female ; General Gynecology ; Gynecology ; Human Genetics ; Human papillomavirus ; Humans ; Mass Screening ; Medical screening ; Medicine ; Medicine & Public Health ; Middle Aged ; Obstetrics/Perinatology/Midwifery ; Papillomaviridae - genetics ; Papillomavirus Infections - complications ; Papillomavirus Infections - diagnosis ; Papillomavirus Infections - epidemiology ; Pregnancy ; Prevalence ; Retrospective Studies ; Uterine Cervical Neoplasms - diagnosis ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - pathology ; Vaginal Smears</subject><ispartof>Archives of gynecology and obstetrics, 2022, Vol.305 (1), p.87-93</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-178e994250ece470462bafc2a223d59eebf0124fce05cd5ebcd9df5eaabb18163</citedby><cites>FETCH-LOGICAL-c419t-178e994250ece470462bafc2a223d59eebf0124fce05cd5ebcd9df5eaabb18163</cites><orcidid>0000-0002-5600-1390</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-021-06208-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-021-06208-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34561716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peace, Stephanie M.</creatorcontrib><creatorcontrib>Jennings, Ashley J.</creatorcontrib><title>Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia (CIN) 3 or cancer within this population.
Methods
We conducted a retrospective chart review of women age 30–65 with intact cervices who had discordant cotesting results between January 1, 2013 and September 1, 2018, at an academic medical center. We used the
t
test for continuous variables and the Chi-square test for categorical variables to compare women with and without CIN3 + . To identify factors associated with CIN3 + , we performed univariate and multivariate logistic regression.
Results
The primary outcome was the prevalence of CIN3 + based on pathologic diagnosis following biopsy or excisional procedure. Among 375 patients with discordant co-testing, the mean age was 43.8 years, 58.4% were parous, and 84.8% were white. Overall, 43/375 (12.0%) had CIN3 + and 7/375 (1.9%) had AIS. On logistic regression, only parity ≥ 1 (
p
= 0.04, adjusted OR = 2.23, CI = 1.06–4.68) was significantly associated with CIN3 + . HPV-18 was less likely to be associated with CIN3 + (
p
= 0.02, adjusted OR 0.08, CI 0.01–0.65) but was present in 43% of AIS cases. HPV16 and other HR-HPV strains were highly associated with CIN3 + .
Conclusion
Women with discordant cotesting are at significant risk for CIN3 + . We recommend that biopsy be performed at the time of indicated colposcopy for all patients with discordant cotesting to assess for high-grade dysplasia.</description><subject>Adult</subject><subject>Aged</subject><subject>Biopsy</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Colposcopy</subject><subject>Early Detection of Cancer</subject><subject>Endocrinology</subject><subject>Female</subject><subject>General Gynecology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Mass Screening</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - diagnosis</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Pregnancy</subject><subject>Prevalence</subject><subject>Retrospective Studies</subject><subject>Uterine Cervical Neoplasms - diagnosis</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Vaginal Smears</subject><issn>0932-0067</issn><issn>1432-0711</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMFO3DAQhq0KVBbaF-gBWeLSQw3jie0kxwrRUgmJPdBeLceZBKNssti7K-3b42WXVuqBk8eab_4ZfYx9kXApAcqrBKBACUApwCBUAj-wmVQFCiilPGIzqHc1mPKEnab0BCCxqsxHdlIobWQpzYzZeaSNG2j0xKeOP4b-UfTRtcTbbVoOLgXHw8j9djUNU78VI_VuFTb0jd_O_4jllMLuxz3FTfBu4N7lpMiTj0RjGPtP7LhzQ6LPh_eM_f5x83B9K-7uf_66_n4nvJL1SsiyorpWqIE8qRKUwcZ1Hh1i0eqaqOny8arzBNq3mhrf1m2nybmmkZU0xRn7us9dxul5TWllFyF5GgY30rROFnVpjNZlDRm9-A99mtZxzNdZNCgrRChUpnBP-TilFKmzyxgWLm6tBLvTb_f6bdZvX_VbzEPnh-h1s6D278ib7wwUeyDl1thT_Lf7ndgXppCQpQ</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Peace, Stephanie M.</creator><creator>Jennings, Ashley J.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5600-1390</orcidid></search><sort><creationdate>2022</creationdate><title>Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening</title><author>Peace, Stephanie M. ; Jennings, Ashley J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-178e994250ece470462bafc2a223d59eebf0124fce05cd5ebcd9df5eaabb18163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biopsy</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Colposcopy</topic><topic>Early Detection of Cancer</topic><topic>Endocrinology</topic><topic>Female</topic><topic>General Gynecology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Mass Screening</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - diagnosis</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Pregnancy</topic><topic>Prevalence</topic><topic>Retrospective Studies</topic><topic>Uterine Cervical Neoplasms - diagnosis</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Vaginal Smears</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peace, Stephanie M.</creatorcontrib><creatorcontrib>Jennings, Ashley J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peace, Stephanie M.</au><au>Jennings, Ashley J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2022</date><risdate>2022</risdate><volume>305</volume><issue>1</issue><spage>87</spage><epage>93</epage><pages>87-93</pages><issn>0932-0067</issn><issn>1432-0711</issn><eissn>1432-0711</eissn><abstract>Purpose
This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia (CIN) 3 or cancer within this population.
Methods
We conducted a retrospective chart review of women age 30–65 with intact cervices who had discordant cotesting results between January 1, 2013 and September 1, 2018, at an academic medical center. We used the
t
test for continuous variables and the Chi-square test for categorical variables to compare women with and without CIN3 + . To identify factors associated with CIN3 + , we performed univariate and multivariate logistic regression.
Results
The primary outcome was the prevalence of CIN3 + based on pathologic diagnosis following biopsy or excisional procedure. Among 375 patients with discordant co-testing, the mean age was 43.8 years, 58.4% were parous, and 84.8% were white. Overall, 43/375 (12.0%) had CIN3 + and 7/375 (1.9%) had AIS. On logistic regression, only parity ≥ 1 (
p
= 0.04, adjusted OR = 2.23, CI = 1.06–4.68) was significantly associated with CIN3 + . HPV-18 was less likely to be associated with CIN3 + (
p
= 0.02, adjusted OR 0.08, CI 0.01–0.65) but was present in 43% of AIS cases. HPV16 and other HR-HPV strains were highly associated with CIN3 + .
Conclusion
Women with discordant cotesting are at significant risk for CIN3 + . We recommend that biopsy be performed at the time of indicated colposcopy for all patients with discordant cotesting to assess for high-grade dysplasia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34561716</pmid><doi>10.1007/s00404-021-06208-2</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5600-1390</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0932-0067 |
ispartof | Archives of gynecology and obstetrics, 2022, Vol.305 (1), p.87-93 |
issn | 0932-0067 1432-0711 1432-0711 |
language | eng |
recordid | cdi_proquest_miscellaneous_2576655790 |
source | MEDLINE; SpringerNature Journals |
subjects | Adult Aged Biopsy Cellular biology Cervical cancer Colposcopy Early Detection of Cancer Endocrinology Female General Gynecology Gynecology Human Genetics Human papillomavirus Humans Mass Screening Medical screening Medicine Medicine & Public Health Middle Aged Obstetrics/Perinatology/Midwifery Papillomaviridae - genetics Papillomavirus Infections - complications Papillomavirus Infections - diagnosis Papillomavirus Infections - epidemiology Pregnancy Prevalence Retrospective Studies Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - pathology Vaginal Smears |
title | Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A42%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20high-grade%20dysplasia%20in%20cytology-negative,%20HPV-positive%20cervical%20cancer%20screening&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Peace,%20Stephanie%20M.&rft.date=2022&rft.volume=305&rft.issue=1&rft.spage=87&rft.epage=93&rft.pages=87-93&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-021-06208-2&rft_dat=%3Cproquest_cross%3E2621822034%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621822034&rft_id=info:pmid/34561716&rfr_iscdi=true |